Skip to main content
Erschienen in: Tumor Biology 7/2016

22.01.2016 | Original Article

Expression of the anti-inflammatory suppressor of cytokine signaling 3 (SOCS3) in human clear cell renal cell carcinoma

verfasst von: Anja Urbschat, Svenja Stumpf, Jörg Hänze, Patrick Paulus, Thorsten J. Maier, Christine Weipert, Rainer Hofmann, Axel Hegele

Erschienen in: Tumor Biology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

The oncogenic transcription factor signal transducer and activator of transcription 3 (STAT3) is a cytokine-activated transcription factor controlling inflammation, cell proliferation, survival, and differentiation in normal tissue as well as in tumor growth. One of its most important negative regulators is the suppressor of cytokine signaling 3 (SOCS3). Here, we analyzed SOCS3 and other tumor-associated local immune regulators in human clear cell renal cell carcinoma (ccRCC). Analyses were performed in tumor and adjacent tumor-free healthy renal tissue from 35 patients with ccRCC. For functional analysis, ccRCC Caki-1 cell lines were stimulated with IL-6 and IFNγ in cell culture assays. We observed significantly lower SOCS3 messenger RNA (mRNA) levels in tumor tissue compared to healthy tissue. SOCS3 mRNA strongly correlated within tumor and healthy tissue. Interestingly vice versa, SOCS3 protein levels were significantly higher in tumor tissue than in healthy tissue. IL-22 and IL-22R1 mRNA displayed no differences in tumor and healthy tissue. Stimulation of Caki-1 cells with IFNγ resulted in markedly increased SOCS3 mRNA levels. We conclude that SOCS3 along with STAT3 participates in regulatory mechanisms in ccRCC, which certainly features only one of multiple factors involved but nevertheless merits further attention.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 2012. Int J Cancer. 2015;136:E359–386.CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 2012. Int J Cancer. 2015;136:E359–386.CrossRefPubMed
2.
Zurück zum Zitat Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23:2763–71.CrossRefPubMed Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23:2763–71.CrossRefPubMed
3.
Zurück zum Zitat Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450:903–7.CrossRefPubMed Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450:903–7.CrossRefPubMed
4.
Zurück zum Zitat Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759–71.CrossRefPubMed Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759–71.CrossRefPubMed
5.
Zurück zum Zitat Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, et al. Japan Immunotherapy S-SGfKC: Stat3 polymorphism can predict the response to interferon-alpha therapy in patients with metastatic renal cell carcinoma. Eur Urol. 2013;63:745–52.CrossRefPubMed Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, et al. Japan Immunotherapy S-SGfKC: Stat3 polymorphism can predict the response to interferon-alpha therapy in patients with metastatic renal cell carcinoma. Eur Urol. 2013;63:745–52.CrossRefPubMed
6.
Zurück zum Zitat Horiguchi A, Asano T, Kuroda K, Sato A, Asakuma J, Ito K, et al. Stat3 inhibitor wp1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer. 2010;102:1592–9.CrossRefPubMedPubMedCentral Horiguchi A, Asano T, Kuroda K, Sato A, Asakuma J, Ito K, et al. Stat3 inhibitor wp1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer. 2010;102:1592–9.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol. 2002;168:762–5.CrossRefPubMed Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol. 2002;168:762–5.CrossRefPubMed
9.
Zurück zum Zitat Yoshimura A, Naka T, Kubo M. Socs proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 2007;7:454–65.CrossRefPubMed Yoshimura A, Naka T, Kubo M. Socs proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 2007;7:454–65.CrossRefPubMed
10.
Zurück zum Zitat Yamamoto K, Yamaguchi M, Miyasaka N, Miura O. Socs-3 inhibits il-12-induced stat4 activation by binding through its sh2 domain to the stat4 docking site in the il-12 receptor beta2 subunit. Biochem Biophys Res Commun. 2003;310:1188–93.CrossRefPubMed Yamamoto K, Yamaguchi M, Miyasaka N, Miura O. Socs-3 inhibits il-12-induced stat4 activation by binding through its sh2 domain to the stat4 docking site in the il-12 receptor beta2 subunit. Biochem Biophys Res Commun. 2003;310:1188–93.CrossRefPubMed
11.
Zurück zum Zitat Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, et al. Cis3/socs3/ssi3 plays a negative regulatory role in stat3 activation and intestinal inflammation. J Exp Med. 2001;193:471–81.CrossRefPubMedPubMedCentral Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, et al. Cis3/socs3/ssi3 plays a negative regulatory role in stat3 activation and intestinal inflammation. J Exp Med. 2001;193:471–81.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, et al. Induction of the cytokine signal regulator socs3/cis3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest. 2001;108:1781–8.CrossRefPubMedPubMedCentral Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, et al. Induction of the cytokine signal regulator socs3/cis3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest. 2001;108:1781–8.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Gomez-Guerrero C, Lopez-Franco O, Sanjuan G, Hernandez-Vargas P, Suzuki Y, Ortiz-Munoz G, et al. Suppressors of cytokine signaling regulate fc receptor signaling and cell activation during immune renal injury. J Immunol. 2004;172:6969–77.CrossRefPubMed Gomez-Guerrero C, Lopez-Franco O, Sanjuan G, Hernandez-Vargas P, Suzuki Y, Ortiz-Munoz G, et al. Suppressors of cytokine signaling regulate fc receptor signaling and cell activation during immune renal injury. J Immunol. 2004;172:6969–77.CrossRefPubMed
14.
Zurück zum Zitat He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, et al. Socs-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A. 2003;100:14133–8.CrossRefPubMedPubMedCentral He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, et al. Socs-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A. 2003;100:14133–8.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Li G, Xu J, Wang Z, Yuan Y, Li Y, Cai S, He Y: Low expression of socs-1 and socs-3 is a poor prognostic indicator for gastric cancer patients. J Cancer Res Clin Oncol 2014. Li G, Xu J, Wang Z, Yuan Y, Li Y, Cai S, He Y: Low expression of socs-1 and socs-3 is a poor prognostic indicator for gastric cancer patients. J Cancer Res Clin Oncol 2014.
16.
Zurück zum Zitat Ogata H, Kobayashi T, Chinen T, Takaki H, Sanada T, Minoda Y, et al. Deletion of the socs3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology. 2006;131:179–93.CrossRefPubMed Ogata H, Kobayashi T, Chinen T, Takaki H, Sanada T, Minoda Y, et al. Deletion of the socs3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology. 2006;131:179–93.CrossRefPubMed
17.
Zurück zum Zitat Stofas A, Levidou G, Piperi C, Adamopoulos C, Dalagiorgou G, Bamias A, et al. The role of cxc-chemokine receptor cxcr2 and suppressor of cytokine signaling-3 (socs-3) in renal cell carcinoma. BMC Cancer. 2014;14:149.CrossRefPubMedPubMedCentral Stofas A, Levidou G, Piperi C, Adamopoulos C, Dalagiorgou G, Bamias A, et al. The role of cxc-chemokine receptor cxcr2 and suppressor of cytokine signaling-3 (socs-3) in renal cell carcinoma. BMC Cancer. 2014;14:149.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Erdogan F, Demirel A, Polat O. Prognostic significance of morphologic parameters in renal cell carcinoma. Int J Clin Pract. 2004;58:333–6.CrossRefPubMed Erdogan F, Demirel A, Polat O. Prognostic significance of morphologic parameters in renal cell carcinoma. Int J Clin Pract. 2004;58:333–6.CrossRefPubMed
19.
Zurück zum Zitat Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T. Prognostic impact of carbonic anhydrase ix expression in human renal cell carcinoma. BJU Int. 2007;100:556–60.CrossRefPubMed Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T. Prognostic impact of carbonic anhydrase ix expression in human renal cell carcinoma. BJU Int. 2007;100:556–60.CrossRefPubMed
20.
Zurück zum Zitat Walther MM, Johnson B, Culley D, Shah R, Weber J, Venzon D, et al. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol. 1998;159:718–22.CrossRefPubMed Walther MM, Johnson B, Culley D, Shah R, Weber J, Venzon D, et al. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol. 1998;159:718–22.CrossRefPubMed
21.
Zurück zum Zitat Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917–21.CrossRefPubMed Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917–21.CrossRefPubMed
22.
Zurück zum Zitat Hoegl S, Bachmann M, Scheiermann P, Goren I, Hofstetter C, Pfeilschifter J, et al. Protective properties of inhaled il-22 in a model of ventilator-induced lung injury. Am J Respir Cell Mol Biol. 2011;44:369–76.CrossRefPubMed Hoegl S, Bachmann M, Scheiermann P, Goren I, Hofstetter C, Pfeilschifter J, et al. Protective properties of inhaled il-22 in a model of ventilator-induced lung injury. Am J Respir Cell Mol Biol. 2011;44:369–76.CrossRefPubMed
23.
Zurück zum Zitat Horiguchi A, Oya M, Marumo K, Murai M. Stat3, but not erks, mediates the il-6-induced proliferation of renal cancer cells, achn and 769p. Kidney Int. 2002;61:926–38.CrossRefPubMed Horiguchi A, Oya M, Marumo K, Murai M. Stat3, but not erks, mediates the il-6-induced proliferation of renal cancer cells, achn and 769p. Kidney Int. 2002;61:926–38.CrossRefPubMed
25.
Zurück zum Zitat Si H, Banga RS, Kapitsinou P, Ramaiah M, Lawrence J, Kambhampati G, et al. Human and murine kidneys show gender- and species-specific gene expression differences in response to injury. PLoS ONE. 2009;4:e4802.CrossRefPubMedPubMedCentral Si H, Banga RS, Kapitsinou P, Ramaiah M, Lawrence J, Kambhampati G, et al. Human and murine kidneys show gender- and species-specific gene expression differences in response to injury. PLoS ONE. 2009;4:e4802.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Neuwirt H, Eder IE, Puhr M, Rudnicki M. Socs-3 is downregulated in progressive ckd patients and regulates proliferation in human renal proximal tubule cells in a stat1/3 independent manner. Lab Investig. 2013;93:123–34.CrossRefPubMed Neuwirt H, Eder IE, Puhr M, Rudnicki M. Socs-3 is downregulated in progressive ckd patients and regulates proliferation in human renal proximal tubule cells in a stat1/3 independent manner. Lab Investig. 2013;93:123–34.CrossRefPubMed
27.
Zurück zum Zitat Thoenes W, Storkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract. 1986;181:125–43.CrossRefPubMed Thoenes W, Storkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract. 1986;181:125–43.CrossRefPubMed
28.
Zurück zum Zitat Guo C, Yang G, Khun K, Kong X, Levy D, Lee P, et al. Activation of stat3 in renal tumors. Am J Transl Res. 2009;1:283–90.PubMedPubMedCentral Guo C, Yang G, Khun K, Kong X, Levy D, Lee P, et al. Activation of stat3 in renal tumors. Am J Transl Res. 2009;1:283–90.PubMedPubMedCentral
29.
Zurück zum Zitat Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Annu Rev Immunol. 2000;18:143–64.CrossRefPubMed Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Annu Rev Immunol. 2000;18:143–64.CrossRefPubMed
30.
Zurück zum Zitat Wolk K, Sabat R. Interleukin-22: a novel t- and nk-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev. 2006;17:367–80.CrossRefPubMed Wolk K, Sabat R. Interleukin-22: a novel t- and nk-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev. 2006;17:367–80.CrossRefPubMed
31.
Zurück zum Zitat Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. Il-22 increases the innate immunity of tissues. Immunity. 2004;21:241–54.CrossRefPubMed Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. Il-22 increases the innate immunity of tissues. Immunity. 2004;21:241–54.CrossRefPubMed
Metadaten
Titel
Expression of the anti-inflammatory suppressor of cytokine signaling 3 (SOCS3) in human clear cell renal cell carcinoma
verfasst von
Anja Urbschat
Svenja Stumpf
Jörg Hänze
Patrick Paulus
Thorsten J. Maier
Christine Weipert
Rainer Hofmann
Axel Hegele
Publikationsdatum
22.01.2016
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 7/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-4857-9

Weitere Artikel der Ausgabe 7/2016

Tumor Biology 7/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.